For breast cancer, YBX1 has been regarded as potential biomarker with poor outcome and silencing YBX1 could inhibit invasive potential through binding its downstream target, such as CORO1C and MMP1 [19, 34–36]. The gene discussed is MMP1; the disease is breast carcinoma.